Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BI 655088 in Healthy Male Subjects
NCT02696616Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2016
- Primary completion
- Feb 2019
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Nanobodies (VHH)
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in chronic kidney disease (CKD) and atherosclerosis comparing BI 655088 with Placebo (2 arms). Primary endpoint: Number of Subjects With Drug-related Adverse Events up to 99 days. Started Mar 2016; status: completed.
02
Drugs
BI 655088
03
Conditions
chronic kidney disease (CKD)atherosclerosis
Beyond the preview
Go deeper on NCT02696616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02696616.